Metabolic profiles are principally different between cancers of the liver, pancreas and breast

International Journal of Biological Sciences

Volumn 10, Issue 9, 2014, Pages 966-972

  Budhu, Anuradha ^a   Terunuma, Atsushi ^a   Zhang, Geng ^a,b   Perwez Hussain, S ^a   Ambs, Stefan ^a   Wang, Xin Wei ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INSTITUTE OF BIOPHYSICS   (China)

Author keywords

Breast; Cancer; Liver; Metabolite; Pancreas

Indexed keywords

TRANSCRIPTOME;

BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; HUMAN; LIVER TUMOR; METABOLISM; METABOLOMICS; PANCREAS TUMOR; PHYSIOLOGY;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; METABOLOMICS; PANCREATIC NEOPLASMS; TRANSCRIPTOME;

EID: 84928165363     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.9810     Document Type: Article

References (21)

1. Levi F, Te VC, Erler G, et al. Epidemiology of unknown primary tumours. Eur J Cancer. 2002; 38:1810-1812.
2. Amela EY, Lauridant-Philippin G, Cousin S, et al. Management of "unfavourable" carcinoma of unknown primary site: synthesis of recent literature. Crit Rev Oncol Hematol. 2012; 84:213-223.
3. Varadhachary GR, Talantov D, Raber MN, et al. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol. 2008; 26:4442-4448.
4. Tothill RW, Li J, Mileshkin L, et al. Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary. J Pathol. 2013;
5. Horlings HM, van Laar RK, Kerst JM, et al. Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol. 2008; 26:4435-4441.
6. Mayordomo JI, Guerra JM, Guijarro C, et al. Neoplasms of unknown primary site: a clinicopathological study of autopsied patients. Tumori. 1993; 79:321-324.
7. Budhu A, Jia HL, Forgues M, et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology. 2008; 47:897-907.
8. Budhu A, Forgues M, Ye QH, et al. Prediction of venous metastases, recurrence and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006; 10:99-111.
9. Zhang G, Schetter A, He P, et al. DPEP1 Inhibits Tumor Cell Invasiveness, Enhances Chemosensitivity and Predicts Clinical Outcome in Pancreatic Ductal Adenocarcinoma. PLoS One. 2012; 7:e31507.
10. Lee EJ, Gusev Y, Jiang J, et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer. 2007; 120:1046-1054.
11. Van de Vijver MJ, He YD, Van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347:1999-2009.
12. Boersma BJ, Reimers M, Yi M, et al. A stromal gene signature associated with inflammatory breast cancer. Int J Cancer. 2008; 122:1324-1332.
13. Hudson RS, Yi M, Esposito D, et al. MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer. Oncogene. 2012;
14. Ramaswamy S, Tamayo P, Rifkin R, et al. Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci U S A. 2001; 98:15149-15154.
15. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006; 103:2257-2261.
16. Sreekumar A, Poisson LM, Rajendiran TM, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009; 457:910-914.
17. Budhu A, Roessler S, Zhao X, et al. Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes. Gastroenterology. 2013; 144:1066-1075.
18. Zhang G, He P, Tan H, et al. Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer. Clin Cancer Res. 2013; 19:4983-4993.
19. Terunuma A, Putluri N, Mishra P, et al. MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J Clin Invest. 2014; 124:398-412.
20. Roessler S, Jia HL, Budhu A, et al. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Research. 2010; 70:10202-10212.
21. Boersma BJ, Howe TM, Goodman JE, et al. Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst. 2006; 98:911-919.